IP Library Granted Patent US 8,546,562
Granted Patent B2
US 8,546,562 · App. 13/457,232 · Granted Oct 1, 2013

Substituted porphyrins

Inventors: James D. Crapo (Englewood, CO); Brian J. Day (Englewood, CO); Michael P. Trova (Schenectady, NY); Polvina Jolicia F. Gauuan (Albany, NY); Douglas B. Kitchen (Schenectady, NY); Irwin Fridovich (Durham, NC); Ines Batinic-Haberle (Durham, NC)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,546,562
App. No.
13/457,232
Granted
Oct 1, 2013
Kind
B2
Abstract

The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

Claims (17)

1. A method of treating an ischemia reperfusion injury, said method comprising administering to a subject in need thereof an effective amount of a compound of formula

or pharmaceutically accept salt thereof,

wherein

said ischemia reperfusion injury is associated with stroke or acute head trauma.

2. The method according to claim 1 , wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

3. The method according to claim 2 , wherein said compound is

4. A method of treating a neurologic disorder, said method comprising administering to a subject in need thereof an effective amount of a compound of formula

or pharmaceutically accept salt thereof,

wherein

said neurologic disorder is Parkinson's disease or amyotrophic lateral sclerosis (ALS).

5. The method according to claim 4 , wherein said neurologic disorder is associated with an over stimulation of an NMDA subtype of a glutamate receptor.

6. The method according to claim 5 , wherein said compound inhibits NMDA induced injury.

7. The method according to claim 4 , wherein said neurologic disorder is Parkinson's disease.

8. The method according to claim 4 , wherein said neurologic disorder is ALS.

9. The method according to claim 4 , wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

10. The method according to claim 9 , wherein said compound is complexed with manganese.

11. The method according to claim 10 , wherein said compound is

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2012
From: FRIDOVICH, IRWIN; BATINIC-HABERLE, INES
To: DUKE UNIVERSITY
Reel/Frame 029267/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2012
From: CRAPO, JAMES D.; DAY, BRIAN J.
To: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
Reel/Frame 029267/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2012
From: TROVA, MICHAEL P.; GAUUAN, POLIVINA JOLICIA F.; KITCHEN, DOUGLAS B.
To: AEOLUS PHARMACEUTICALS, INC.
Reel/Frame 029267/0085 →
CHANGE OF NAME Recorded Nov 8, 2012
From: AEOLUS PHARMACEUTICALS, INC.
To: AEOLUS SCIENCES, INC.
Reel/Frame 029275/0496 →
CHANGE OF NAME Recorded Nov 8, 2012
From: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
To: NATIONAL JEWISH HEALTH
Reel/Frame 029275/0499 →
Continuity (6)
Continuation 12885198 · Sep 17, 2010
Continuation 11424662 · Jun 16, 2006
Division 10349171 · Jan 23, 2003
Continuation 09490537 · Jan 25, 2000
Provisional Application 60117010 · Jan 25, 1999
Related Publication 20120214780A1 · Aug 23, 2012